aclidinium vs fluticasone/vilanterol
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of aclidinium and fluticasone/vilanterol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Breo Ellipta
No summary available.
Breo Ellipta is a medicine that contains a corticosteroid and a long-acting beta-agonist. It is used to help control symptoms of COPD and asthma.
Information not available.
Breo Ellipta is used to treat COPD in adults. It is also used to treat asthma in people ages 5 and older. This medicine helps to improve your breathing by reducing inflammation and opening airways.
Information not available.
Breo Ellipta contains two medicines. Fluticasone furoate reduces inflammation in the lungs. Vilanterol helps to relax the muscles around your airways, making it easier to breathe.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Sore throat
- • Upper respiratory infection
- • Headache
- • Mouth infection (oral candidiasis)
- • Back pain
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
No adverse event reports.
No specific warnings noted.
LABA medicines such as vilanterol, when used alone, increase the risk of asthma-related death. Breo Ellipta should not be used to treat sudden breathing problems. Do not use Breo Ellipta with other medicines that contain a LABA.
No pregnancy information available.
Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if Breo Ellipta will harm your unborn baby. Breo Ellipta should be used during late pregnancy only if the potential benefit justifies the potential risk.
Also Compare, Nearby Drugs
Compare aclidinium with
Compare fluticasone/vilanterol with
How to Read This aclidinium vs fluticasone/vilanterol Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while fluticasone/vilanterol sits within the Corticosteroid / Long-Acting Beta-2 Agonist Combination class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while fluticasone/vilanterol has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aclidinium or fluticasone/vilanterol.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.